Explore - Molecular AOP Builder

Filter by AOP

Confidence

KE ID	KE Title	WikiPathways ID	WikiPathways Title	Confidence Level	Proposer	Curator	Last updated	AOP context	Actions

KE ID	KE Title	GO ID	GO Name	Connection Type	Confidence Level	Proposer	Last updated	AOP context
KE 195	Inhibition, NMDARs	GO:2000310	regulation of NMDA receptor activity	describes	high	marvinm2	2026-08-15	AOP 12, AOP 13, AOP 522
KE 52	Decreased, Calcium influx	GO:0070509	calcium ion import	describes	high	marvinm2	2026-08-15	AOP 12, AOP 13
KE 381	Reduced levels of BDNF	GO:0032898	neurotrophin production	describes	high	marvinm2	2026-08-15	AOP 12, AOP 13, AOP 375, AOP 54, AOP 610
KE 382	Aberrant, Dendritic morphology	GO:0048813	dendrite morphogenesis	describes	high	marvinm2	2026-08-15	AOP 13
KE 383	Reduced, Presynaptic release of glutamate	GO:0061535	glutamate secretion, neurotransmission	describes	high	marvinm2	2026-08-15	AOP 13
KE 385	Decrease of synaptogenesis	GO:0007416	synapse assembly	describes	high	marvinm2	2026-08-15	AOP 13, AOP 533, AOP 54, AOP 610
KE 386	Decrease of neuronal network function	GO:0007268	chemical synaptic transmission	involves	medium	marvinm2	2026-08-15	AOP 13, AOP 17, AOP 405, AOP 429, AOP 475, AOP 501, AOP 522, AOP 533, AOP 54, AOP 610, AOP 636, AOP 78, AOP 90
KE 341	Impairment, Learning and memory	GO:0007611	learning or memory	describes	high	marvinm2	2026-08-15	AOP 12, AOP 13, AOP 17, AOP 475, AOP 48, AOP 483, AOP 490, AOP 499, AOP 500, AOP 520, AOP 525, AOP 533, AOP 535, AOP 54, AOP 610, AOP 77, AOP 78, AOP 87, AOP 88, AOP 89, AOP 90, AOP 99
KE 115	Increase, FA Influx	GO:2000191	regulation of fatty acid transport	describes	high	marvinm2	2026-07-29	AOP 34, AOP 517
KE 228	peroxisome proliferator activated receptor promoter demethylation	GO:0035357	peroxisome proliferator activated receptor signaling pathway	context	medium	marvinm2	2026-07-29	AOP 34, AOP 510, AOP 58, AOP 72
KE 898	Disruption, Lysosome	GO:1903008	organelle disassembly	related	medium	marvinm2	2026-07-29	AOP 144, AOP 257, AOP 530
KE 1115	Increase, Reactive oxygen species	GO:1903409	reactive oxygen species biosynthetic process	describes	high	marvinm2	2026-07-29	AOP 186, AOP 207, AOP 213, AOP 26, AOP 27, AOP 273, AOP 282, AOP 298, AOP 299, AOP 303, AOP 311, AOP 319, AOP 324, AOP 325, AOP 326, AOP 327, AOP 328, AOP 329, AOP 330, AOP 331, AOP 332, AOP 333, AOP 382, AOP 383, AOP 384, AOP 386, AOP 387, AOP 396, AOP 409, AOP 413, AOP 416, AOP 418, AOP 423, AOP 451, AOP 462, AOP 472, AOP 476, AOP 481, AOP 488, AOP 492, AOP 497, AOP 500, AOP 505, AOP 511, AOP 513, AOP 521, AOP 534, AOP 540, AOP 569, AOP 595, AOP 596, AOP 598, AOP 599, AOP 600, AOP 601, AOP 602, AOP 603, AOP 608, AOP 613, AOP 622, AOP 636, AOP 638
KE 1492	Tissue resident cell activation	GO:0002263	cell activation involved in immune response	describes	medium	marvinm2	2026-07-29	AOP 17, AOP 293, AOP 294, AOP 38, AOP 483
KE 1493	Increased Pro-inflammatory mediators	GO:0002526	acute inflammatory response	involves	medium	marvinm2	2026-07-29	AOP 144, AOP 17, AOP 293, AOP 294, AOP 377, AOP 38, AOP 432, AOP 470
KE 10	Acetylcholine accumulation in synapses	GO:0001507	acetylcholine catabolic process in synaptic cleft	involves	medium	marvinm2	2026-07-28	AOP 16, AOP 281, AOP 312, AOP 405, AOP 471
KE 10	Acetylcholine accumulation in synapses	GO:0061526	acetylcholine secretion	involves	medium	marvinm2	2026-07-28	AOP 16, AOP 281, AOP 312, AOP 405, AOP 471
KE 50	Increase, Ca++ (intracellular)	GO:0006874	intracellular calcium ion homeostasis	describes	high	marvinm2	2026-07-28	AOP 26
KE 357	Cholestasis, Pathology	GO:0032782	bile acid secretion	context	medium	marvinm2	2026-07-28	AOP 27
KE 1391	Activation of Cyp2E1	GO:0006805	xenobiotic metabolic process	describes	medium	marvinm2	2026-07-28	AOP 220, AOP 450
KE 105	Inhibition, Mitochondrial Electron Transport Chain Complexes	GO:0022904	respiratory electron transport chain	describes	high	marvinm2	2026-07-28	AOP 437, AOP 447, AOP 479, AOP 480
KE 178	Mitochondrial electron transport chain, disrupted	GO:0022904	respiratory electron transport chain	describes	high	marvinm2	2026-07-28	AOP 26, AOP 284, AOP 564, AOP 590
KE 193	Decreased, Nitric Oxide	GO:0046209	nitric oxide metabolic process	describes	high	marvinm2	2026-07-28	AOP 26
KE 201	Binding of antagonist, NMDA receptors	GO:0098989	NMDA selective glutamate receptor signaling pathway	involves	high	marvinm2	2026-07-28	AOP 12, AOP 13
KE 220	Increase, Plasma vitellogenin concentrations	GO:0007296	vitellogenesis	describes	high	marvinm2	2026-07-28	AOP 29, AOP 53, AOP 536, AOP 537
KE 291	Accumulation, Triglyceride	GO:0030730	triglyceride storage	describes	high	marvinm2	2026-07-28	AOP 318, AOP 34, AOP 517, AOP 518, AOP 529, AOP 57, AOP 580, AOP 591
KE 327	Accumulation, Fatty acid	GO:0006631	fatty acid metabolic process	involves	medium	marvinm2	2026-07-28	AOP 36, AOP 529, AOP 57, AOP 58, AOP 60
KE 327	Accumulation, Fatty acid	GO:0015908	fatty acid transport	involves	medium	marvinm2	2026-07-28	AOP 36, AOP 529, AOP 57, AOP 58, AOP 60
KE 345	N/A, Liver Steatosis	GO:0019915	lipid storage	related	medium	marvinm2	2026-07-28	AOP 34
KE 637	impaired, Learning and memory	GO:0007611	learning or memory	describes	high	marvinm2	2026-07-28	AOP 471
KE 708	Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium)	GO:0097017	renal protein absorption	describes	medium	marvinm2	2026-07-28	AOP 105
KE 771	Decrease, Serum thyroid hormone (T4/T3)	GO:0042403	thyroid hormone metabolic process	describes	high	marvinm2	2026-07-28	AOP 402
KE 829	Damage, Lipid bilayer	GO:0061024	membrane organization	related	medium	marvinm2	2026-07-28	AOP 130
KE 831	Disturbance, Lysosomal function	GO:0007040	lysosome organization	related	medium	marvinm2	2026-07-28	AOP 130, AOP 257
KE 896	Parkinsonian motor deficits	GO:0007626	locomotory behavior	context	medium	marvinm2	2026-07-28	AOP 3, AOP 464, AOP 471, AOP 587, AOP 588, AOP 589, AOP 593
KE 958	Displacement, Serum thyroxine (T4) from transthyretin	GO:0070327	thyroid hormone transport	describes	medium	marvinm2	2026-07-28	AOP 152
KE 959	Increased, Free serum thyroxine (T4)	GO:0070327	thyroid hormone transport	related	medium	marvinm2	2026-07-28	AOP 152, AOP 366, AOP 367
KE 1023	Increased, Thyroid-stimulating hormone (TSH)	GO:0070460	thyroid-stimulating hormone secretion	describes	high	marvinm2	2026-07-28	AOP 110, AOP 119, AOP 162, AOP 190
KE 1096	Increased, blood uric acid concentration	GO:0046415	urate metabolic process	involves	medium	marvinm2	2026-07-28	AOP 138, AOP 177
KE 1096	Increased, blood uric acid concentration	GO:0015747	urate transport	involves	medium	marvinm2	2026-07-28	AOP 138, AOP 177
KE 1098	Increased, blood potassium concentration	GO:0055075	potassium ion homeostasis	describes	high	marvinm2	2026-07-28	AOP 138, AOP 177, AOP 186, AOP 551
KE 1290	Glutathione homeostasis	GO:0006749	glutathione metabolic process	describes	high	marvinm2	2026-07-28	AOP 209
KE 1351	Activated, NMDA receptor	GO:0098989	NMDA selective glutamate receptor signaling pathway	involves	high	marvinm2	2026-07-28	AOP 215, AOP 230
KE 1393	Hepatocytotoxicity	GO:0008219	cell death	related	medium	marvinm2	2026-07-28	AOP 220
KE 1413	Reduced, presynaptic neuron 2 activity	GO:0098928	presynaptic signal transduction	involves	medium	marvinm2	2026-07-28	AOP 231
KE 1414	Decreased, GABA	GO:0009449	GABA biosynthetic process	involves	medium	marvinm2	2026-07-28	AOP 231
KE 1414	Decreased, GABA	GO:0014051	gamma-aminobutyric acid secretion	involves	medium	marvinm2	2026-07-28	AOP 231
KE 1415	Reduced, GABA-A receptor activation	GO:0007214	gamma-aminobutyric acid signaling pathway	involves	high	marvinm2	2026-07-28	AOP 231
KE 1416	Decreased, intracellular chloride	GO:0030644	intracellular chloride ion homeostasis	describes	high	marvinm2	2026-07-28	AOP 231
KE 1417	NFE2/Nrf2 repression	GO:0034599	cellular response to oxidative stress	related	medium	marvinm2	2026-07-28	AOP 232, AOP 507, AOP 508, AOP 509, AOP 615
KE 1419	Reduced, FXR activity	GO:0038185	nuclear receptor-mediated bile acid signaling pathway	involves	medium	marvinm2	2026-07-28	-
KE 1421	Activated, LXR	GO:0141193	nuclear receptor-mediated signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 232
KE 1422	Reduced, PPARalpha	GO:0035357	peroxisome proliferator activated receptor signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 232
KE 1423	Reduced, HSD17B4 activity	GO:0006635	fatty acid beta-oxidation	related	medium	marvinm2	2026-07-28	AOP 232
KE 1424	Reduced, fatty acid beta oxidation	GO:0006635	fatty acid beta-oxidation	describes	high	marvinm2	2026-07-28	AOP 232
KE 1456	Increase, Differentiation of fibroblasts	GO:0048762	mesenchymal cell differentiation	describes	medium	marvinm2	2026-07-28	AOP 241
KE 1458	Pulmonary fibrosis	GO:0030198	extracellular matrix organization	related	medium	marvinm2	2026-07-28	AOP 173, AOP 241, AOP 347, AOP 481
KE 1468	Activation, Latent Transforming Growth Factor Beta 1	GO:0071604	transforming growth factor beta production	related	medium	marvinm2	2026-07-28	AOP 241
KE 1469	Activation, Transforming Growth Factor beta pathway	GO:0007179	transforming growth factor beta receptor signaling pathway	describes	high	marvinm2	2026-07-28	AOP 241
KE 1481	Inhibition of mitochondrial DNA polymerase gamma (Pol gamma)	GO:0006264	mitochondrial DNA replication	describes	high	marvinm2	2026-07-28	AOP 256
KE 1482	Depletion, mtDNA	GO:0032042	mitochondrial DNA metabolic process	describes	medium	marvinm2	2026-07-28	AOP 256
KE 1486	Binding of substrate, endocytic receptor	GO:0006898	receptor-mediated endocytosis	describes	high	marvinm2	2026-07-28	AOP 257
KE 1488	Glutamate dyshomeostasis	GO:0090461	intracellular glutamate homeostasis	describes	high	marvinm2	2026-07-28	AOP 17
KE 1491	Increased, Oncotic Necrosis	GO:0008219	cell death	related	low	marvinm2	2026-07-28	AOP 213
KE 1498	Loss of alveolar capillary membrane integrity	GO:0061028	establishment of endothelial barrier	describes	medium	marvinm2	2026-07-28	AOP 173, AOP 302
KE 1499	Increased, activation of T (T) helper (h) type 2 cells	GO:0035712	T-helper 2 cell activation	describes	high	marvinm2	2026-07-28	AOP 173
KE 1500	Increased, fibroblast proliferation and myofibroblast differentiation	GO:0048144	fibroblast proliferation	involves	medium	marvinm2	2026-07-28	AOP 173
KE 1500	Increased, fibroblast proliferation and myofibroblast differentiation	GO:0036446	myofibroblast differentiation	involves	medium	marvinm2	2026-07-28	AOP 173
KE 1501	Increased, extracellular matrix deposition	GO:0085029	extracellular matrix assembly	describes	medium	marvinm2	2026-07-28	AOP 383, AOP 414, AOP 415, AOP 494
KE 1508	CYP2E1 Activation	GO:0006805	xenobiotic metabolic process	describes	medium	marvinm2	2026-07-28	AOP 260
KE 1509	Protein Adduct Formation	GO:0008213	protein alkylation	describes	medium	marvinm2	2026-07-28	AOP 260
KE 1511	Lipid Peroxidation	GO:0034440	lipid oxidation	related	high	marvinm2	2026-07-28	AOP 260
KE 1512	Unfolded Protein Response	GO:0030968	endoplasmic reticulum unfolded protein response	describes	high	marvinm2	2026-07-28	AOP 260, AOP 285, AOP 464
KE 1514	Neurodegeneration	GO:0008219	cell death	related	medium	marvinm2	2026-07-28	AOP 260
KE 1527	Increase, Cell membrane depolarization	GO:0051899	membrane depolarization	describes	high	marvinm2	2026-07-28	AOP 266, AOP 361, AOP 464
KE 1538	Decreased protection against oxidative stress	GO:0034599	cellular response to oxidative stress	describes	high	marvinm2	2026-07-28	AOP 17, AOP 284
KE 1541	Mitochondrial Complex I inhibition	GO:0006120	mitochondrial electron transport, NADH to ubiquinone	describes	high	marvinm2	2026-07-28	AOP 564
KE 1542	Inhibition, Mitochondrial complex III	GO:0006122	mitochondrial electron transport, ubiquinol to cytochrome c	describes	high	marvinm2	2026-07-28	AOP 273, AOP 286, AOP 287, AOP 587
KE 1543	Mitochondrial Complex IV inhibition	GO:0006123	mitochondrial electron transport, cytochrome c to oxygen	describes	high	marvinm2	2026-07-28	AOP 273, AOP 589
KE 1544	Mitochondrial Complex V inhibition	GO:0042776	proton motive force-driven mitochondrial ATP synthesis	describes	medium	marvinm2	2026-07-28	AOP 273
KE 1545	Decreased, mitochondrial oxidative phosphorylation	GO:0006119	oxidative phosphorylation	describes	high	marvinm2	2026-07-28	AOP 273, AOP 567
KE 1547	Mitochondrial Injury	GO:0007005	mitochondrion organization	related	medium	marvinm2	2026-07-28	AOP 273, AOP 464
KE 1548	Necrotic Tissue	GO:0008219	cell death	related	low	marvinm2	2026-07-28	AOP 273, AOP 278
KE 1574	Inhibition, IKK complex	GO:0007249	canonical NF-kappaB signal transduction	involves	medium	marvinm2	2026-07-28	AOP 278
KE 1575	Activation, Caspase 8 pathway	GO:0008625	extrinsic apoptotic signaling pathway via death domain receptors	describes	medium	marvinm2	2026-07-28	AOP 278
KE 1576	Activation, Tissue resident cells (Kuppfer cells)	GO:0042116	macrophage activation	describes	high	marvinm2	2026-07-28	AOP 278
KE 1579	Increase, proinflammatory mediators (TNFalpha)	GO:0032640	tumor necrosis factor production	describes	high	marvinm2	2026-07-28	AOP 278
KE 1580	Binding of microtubule stabilizing agents (MSA) to microtubules	GO:0000226	microtubule cytoskeleton organization	related	medium	marvinm2	2026-07-28	AOP 279
KE 1581	Disturbance in microtubule dynamic instability	GO:0046785	microtubule polymerization	involves	medium	marvinm2	2026-07-28	AOP 279
KE 1581	Disturbance in microtubule dynamic instability	GO:0007019	microtubule depolymerization	involves	medium	marvinm2	2026-07-28	AOP 279
KE 1582	Impaired axonial transport	GO:0098930	axonal transport	describes	high	marvinm2	2026-07-28	AOP 279, AOP 429, AOP 471
KE 1584	Interaction of α-diketones with arginine residues	GO:0018195	peptidyl-arginine modification	describes	medium	marvinm2	2026-07-28	AOP 280
KE 1585	Proteasomal dysfunction	GO:0010498	proteasomal protein catabolic process	related	medium	marvinm2	2026-07-28	AOP 280, AOP 464
KE 1586	Airway epithelial injury	GO:0009611	response to wounding	related	medium	marvinm2	2026-07-28	AOP 280, AOP 481
KE 1587	Fibroproliferative airway lesions	GO:0030198	extracellular matrix organization	describes	medium	marvinm2	2026-07-28	AOP 280
KE 1604	Inhibition of N-linked glycosylation	GO:0006487	protein N-linked glycosylation	describes	high	marvinm2	2026-07-28	AOP 285
KE 1605	Accumulation of misfolded proteins	GO:0006515	protein quality control for misfolded or incompletely synthesized proteins	involves	medium	marvinm2	2026-07-28	AOP 285, AOP 464
KE 1605	Accumulation of misfolded proteins	GO:0006457	protein folding	involves	high	marvinm2	2026-07-28	AOP 285, AOP 464
KE 1606	Activation of hepatic stellate cells	GO:0035733	hepatic stellate cell activation	describes	high	marvinm2	2026-07-28	AOP 285
KE 1607	Increase, Necrosis	GO:0008219	cell death	related	low	marvinm2	2026-07-28	AOP 413
KE 1633	Increase in inflammation	GO:0006954	inflammatory response	describes	high	marvinm2	2026-07-28	AOP 362, AOP 447, AOP 493
KE 1653	Binding of inhibitor to mitochondrial complex III	GO:0006122	mitochondrial electron transport, ubiquinol to cytochrome c	describes	medium	marvinm2	2026-07-28	AOP 273
KE 1654	Binding of inhibitor to mitochondrial complex IV	GO:0006123	mitochondrial electron transport, cytochrome c to oxygen	describes	medium	marvinm2	2026-07-28	AOP 273
KE 1655	Binding of inhibitor to mitochondrial complex V	GO:0042776	proton motive force-driven mitochondrial ATP synthesis	describes	medium	marvinm2	2026-07-28	AOP 273
KE 1656	Antagonism, Thyroid Receptor	GO:0002154	thyroid hormone receptor signaling pathway	involves	high	marvinm2	2026-07-28	AOP 300, AOP 485, AOP 525, AOP 610
KE 1672	Inhibition of lung surfactant function	GO:0043129	surfactant homeostasis	describes	high	marvinm2	2026-07-28	AOP 302
KE 1677	Reduced tidal volume	GO:0003016	respiratory system process	related	low	marvinm2	2026-07-28	AOP 302
KE 1708	Th17 cell migration and inflammation induction	GO:0072538	T-helper 17 type immune response	describes	medium	marvinm2	2026-07-28	AOP 313, AOP 377
KE 1740	Induced dysregulation of ACE2	GO:0002003	angiotensin maturation	related	medium	marvinm2	2026-07-28	AOP 319, AOP 383
KE 1743	Increase plasma Ang II	GO:0002003	angiotensin maturation	describes	medium	marvinm2	2026-07-28	AOP 383
KE 1750	Increased inflammatory immune responses	GO:0006954	inflammatory response	describes	high	marvinm2	2026-07-28	AOP 320, AOP 426
KE 1752	Increased Angiotensin II	GO:0002003	angiotensin maturation	describes	medium	marvinm2	2026-07-28	AOP 319, AOP 381, AOP 384, AOP 385
KE 1770	Decrease, Mitochondrial membrane potential	GO:0051882	mitochondrial depolarization	describes	medium	marvinm2	2026-07-28	AOP 328, AOP 387, AOP 447
KE 1792	Toll-like receptor 4 activation	GO:0034142	toll-like receptor 4 signaling pathway	involves	high	marvinm2	2026-07-28	AOP 347
KE 1794	Pin-1 activation	GO:0000413	protein peptidyl-prolyl isomerization	describes	high	marvinm2	2026-07-28	AOP 347
KE 1795	Latent Transforming growth Factor beta expression	GO:0071604	transforming growth factor beta production	describes	high	marvinm2	2026-07-28	AOP 347
KE 1812	Increase, Cytochrome c release	GO:0001836	release of cytochrome c from mitochondria	describes	high	marvinm2	2026-07-28	AOP 464
KE 1814	benzoquinone imine and acylglucuronide metabolites	GO:0042178	xenobiotic catabolic process	describes	medium	marvinm2	2026-07-28	AOP 362
KE 1815	Activation of ER stress	GO:0034976	response to endoplasmic reticulum stress	describes	high	marvinm2	2026-07-28	AOP 362, AOP 447, AOP 626, AOP 629
KE 1817	Apoptotic cell death	GO:0006915	apoptotic process	describes	high	marvinm2	2026-07-28	AOP 362, AOP 423
KE 1818	Immune cell activation	GO:0002263	cell activation involved in immune response	describes	high	marvinm2	2026-07-28	AOP 362
KE 1819	IFNγ signaling	GO:0060333	type II interferon-mediated signaling pathway	describes	high	marvinm2	2026-07-28	AOP 362
KE 1820	Immune mediated hepatitis	GO:0002384	hepatic immune response	describes	medium	marvinm2	2026-07-28	AOP 362
KE 1829	Altered, Thyroid hormone-dependent gene expression	GO:0097066	response to thyroid hormone	describes	medium	marvinm2	2026-07-28	AOP 190, AOP 191, AOP 393, AOP 402
KE 1834	Decrease, Acyl-CoA dehydrogenases	GO:0033539	fatty acid beta-oxidation using acyl-CoA dehydrogenase	describes	high	marvinm2	2026-07-28	AOP 318
KE 1841	Encephalitis	GO:0150076	neuroinflammatory response	describes	medium	marvinm2	2026-07-28	AOP 374, AOP 471
KE 1842	Prolonged TLR9 activation	GO:0034162	toll-like receptor 9 signaling pathway	involves	high	marvinm2	2026-07-28	AOP 377
KE 1844	systemic inflammatory response syndrome	GO:0006954	inflammatory response	context	medium	marvinm2	2026-07-28	AOP 377, AOP 393
KE 1848	Toll Like Receptor (TLR) Dysregulation	GO:0002224	toll-like receptor signaling pathway	involves	high	marvinm2	2026-07-28	AOP 320, AOP 377, AOP 378
KE 1851	Binding of agonist, Angiotensin II receptor type 1 receptor (AT1R)	GO:0038166	angiotensin-activated signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 319, AOP 382
KE 1852	Increased Ang II type 1 receptor (AT1R)	GO:0038166	angiotensin-activated signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 383, AOP 384
KE 1853	Hyperactivation of ACE/Ang-II/AT1R axis	GO:0002003	angiotensin maturation	involves	medium	marvinm2	2026-07-28	AOP 384, AOP 427
KE 1853	Hyperactivation of ACE/Ang-II/AT1R axis	GO:0038166	angiotensin-activated signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 384, AOP 427
KE 1855	Increased Sodium-sensitive hypertension	GO:0008217	regulation of blood pressure	describes	medium	marvinm2	2026-07-28	AOP 384
KE 1857	Platelet-neutrophil interactions, Increased	GO:0002283	neutrophil activation involved in immune response	related	medium	marvinm2	2026-07-28	AOP 377, AOP 412
KE 1897	increased MyD88 activation	GO:0002755	MyD88-dependent toll-like receptor signaling pathway	involves	high	marvinm2	2026-07-28	AOP 377
KE 1899	formation of neutrophil extracellular traps (NETs)	GO:0140645	neutrophil extracellular trap formation	describes	high	marvinm2	2026-07-28	AOP 377
KE 1900	increased platelet surface TLR9 expression	GO:0034394	protein localization to cell surface	related	medium	marvinm2	2026-07-28	AOP 377
KE 1907	Airway Surface Liquid Height, Decreased	GO:0035377	transepithelial water transport	involves	medium	marvinm2	2026-07-28	AOP 424
KE 1907	Airway Surface Liquid Height, Decreased	GO:0030321	transepithelial chloride transport	involves	medium	marvinm2	2026-07-28	AOP 424
KE 1912	Motile Cilia Number/Length, Decreased	GO:0044458	motile cilium assembly	describes	high	marvinm2	2026-07-28	AOP 425
KE 1917	Altered gene expression, NRF2 dependent antioxidant pathway	GO:0034599	cellular response to oxidative stress	describes	medium	marvinm2	2026-07-28	AOP 420, AOP 421, AOP 447
KE 1921	Altered gene expression, NF-kB dependent Interleukin-6 pathway	GO:0032635	interleukin-6 production	involves	medium	marvinm2	2026-07-28	AOP 415, AOP 416
KE 1921	Altered gene expression, NF-kB dependent Interleukin-6 pathway	GO:0007249	canonical NF-kappaB signal transduction	involves	medium	marvinm2	2026-07-28	AOP 415, AOP 416
KE 1922	Increased, Reactive metabolites production	GO:0006805	xenobiotic metabolic process	related	low	marvinm2	2026-07-28	AOP 417
KE 1923	Altered gene expression, P53 dependent apoptosis pathway	GO:0072332	intrinsic apoptotic signaling pathway by p53 class mediator	describes	high	marvinm2	2026-07-28	AOP 419
KE 1933	Increased, Interleukin-6 production	GO:0032635	interleukin-6 production	describes	high	marvinm2	2026-07-28	AOP 416
KE 1941	Memory Loss	GO:0007613	memory	describes	medium	marvinm2	2026-07-28	AOP 429
KE 1942	Accumulation, Cytosolic toxic Tau oligomers	GO:1990000	amyloid fibril formation	related	medium	marvinm2	2026-07-28	AOP 429
KE 1943	Hyperphosphorylation of Tau	GO:0006468	protein phosphorylation	related	medium	marvinm2	2026-07-28	AOP 429
KE 1944	Synaptic dysfunction	GO:0099536	synaptic signaling	describes	high	marvinm2	2026-07-28	AOP 429, AOP 471, AOP 475
KE 1945	Dysfunctional Autophagy	GO:0006914	autophagy	describes	high	marvinm2	2026-07-28	AOP 429, AOP 452
KE 1978	Increase risk, microcephaly	GO:0007420	brain development	context	medium	marvinm2	2026-07-28	AOP 441, AOP 523
KE 2005	Altered neurotransmission in development	GO:0007268	chemical synaptic transmission	describes	high	marvinm2	2026-07-28	AOP 442
KE 2007	Non-coding RNA expression profile alteration	GO:0070918	regulatory ncRNA processing	related	medium	marvinm2	2026-07-28	AOP 452
KE 2009	Activation of inflammation pathway	GO:0006954	inflammatory response	describes	high	marvinm2	2026-07-28	AOP 452, AOP 507, AOP 511, AOP 638
KE 2010	Pulmonary inflammation	GO:0006954	inflammatory response	describes	medium	marvinm2	2026-07-28	AOP 452, AOP 481
KE 2012	Fibroblast proliferation and differentiation	GO:0048144	fibroblast proliferation	involves	medium	marvinm2	2026-07-28	AOP 452
KE 2012	Fibroblast proliferation and differentiation	GO:0048762	mesenchymal cell differentiation	involves	medium	marvinm2	2026-07-28	AOP 452
KE 2013	Airway remodeling	GO:0048771	tissue remodeling	describes	medium	marvinm2	2026-07-28	AOP 452
KE 2017	Endoplasmic reticulum stress	GO:0034976	response to endoplasmic reticulum stress	describes	high	marvinm2	2026-07-28	AOP 454, AOP 464
KE 2029	protein-coupled estrogen receptor 1 (GPER) activation	GO:0030520	estrogen receptor signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 401, AOP 535
KE 2030	Activation, PARP1	GO:0070212	protein poly-ADP-ribosylation	describes	medium	marvinm2	2026-07-28	AOP 423
KE 2031	Releasing, Apoptosis-Inducing Factor (AIF)	GO:0097190	apoptotic signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 423
KE 2036	Activation of metabotropic glutamate receptor	GO:0007216	G protein-coupled glutamate receptor signaling pathway	involves	high	marvinm2	2026-07-28	AOP 464
KE 2037	Inositol triphosphate receptor activation	GO:1903514	release of sequestered calcium ion into cytosol by endoplasmic reticulum	describes	medium	marvinm2	2026-07-28	AOP 464, AOP 490
KE 2038	Activation of calpain signalling	GO:0006508	proteolysis	related	medium	marvinm2	2026-07-28	AOP 464
KE 2039	Inhibition GABAA receptor	GO:0007214	gamma-aminobutyric acid signaling pathway	involves	high	marvinm2	2026-07-28	AOP 464
KE 2085	Pulmonary epithelial injury	GO:0009611	response to wounding	related	medium	marvinm2	2026-07-28	AOP 481
KE 2086	Airway inflammation	GO:0006954	inflammatory response	describes	high	marvinm2	2026-07-28	AOP 481
KE 2088	Dysfunction of respiratory system	GO:0003016	respiratory system process	context	high	marvinm2	2026-07-28	AOP 481
KE 2093	Brain thyroid hormone (T4/T3) decreased	GO:0042403	thyroid hormone metabolic process	involves	medium	marvinm2	2026-07-28	AOP 402, AOP 610
KE 2093	Brain thyroid hormone (T4/T3) decreased	GO:0070327	thyroid hormone transport	involves	medium	marvinm2	2026-07-28	AOP 402, AOP 610
KE 2094	Abnormal, neuroblast migration	GO:0097402	neuroblast migration	describes	high	marvinm2	2026-07-28	AOP 402
KE 2107	Hypomyelination	GO:0042552	myelination	describes	high	marvinm2	2026-07-28	AOP 485, AOP 487, AOP 488, AOP 489, AOP 525, AOP 605, AOP 608
KE 2108	Altered, white brain matter	GO:0042552	myelination	related	medium	marvinm2	2026-07-28	AOP 485, AOP 487, AOP 488, AOP 489, AOP 525, AOP 610
KE 2109	Binding, extracellular matrix protein laminin	GO:0007160	cell-matrix adhesion	describes	medium	marvinm2	2026-07-28	AOP 486
KE 2110	Disrupted binding, laminin-beta1-integrin receptors with laminin	GO:0007160	cell-matrix adhesion	describes	medium	marvinm2	2026-07-28	AOP 486
KE 2111	Decreased, neural progenitor cell adhesion to laminin	GO:0007160	cell-matrix adhesion	describes	medium	marvinm2	2026-07-28	AOP 486
KE 2112	Disturbed, radial glia cell alignment and migration	GO:0008347	glial cell migration	describes	medium	marvinm2	2026-07-28	AOP 486
KE 2113	Decreased, radial glia cell density	GO:0014009	glial cell proliferation	involves	medium	marvinm2	2026-07-28	AOP 486
KE 2113	Decreased, radial glia cell density	GO:0010001	glial cell differentiation	involves	medium	marvinm2	2026-07-28	AOP 486
KE 2114	Disturbed, cortical architecture	GO:0021987	cerebral cortex development	related	medium	marvinm2	2026-07-28	AOP 486
KE 2115	Altered, cholesterol metabolism	GO:0008203	cholesterol metabolic process	describes	high	marvinm2	2026-07-28	AOP 487, AOP 525
KE 2116	Decreased, oligodendrocyte differentiation	GO:0048709	oligodendrocyte differentiation	describes	high	marvinm2	2026-07-28	AOP 487, AOP 488, AOP 489
KE 2117	Increase, goblet cell number	GO:0060480	lung goblet cell differentiation	describes	high	marvinm2	2026-07-28	AOP 148
KE 2148	Increased LCN2/iron complex binds to SLC22A17 receptor in neuron	GO:0006898	receptor-mediated endocytosis	related	medium	marvinm2	2026-07-28	AOP 498
KE 2149	Increased intracelluar Iron accumulation	GO:0006879	intracellular iron ion homeostasis	describes	high	marvinm2	2026-07-28	AOP 498, AOP 501
KE 2187	Opening, voltage-gated calcium channels	GO:0070588	calcium ion transmembrane transport	describes	medium	marvinm2	2026-07-28	AOP 464
KE 2188	Activation, caspases	GO:0097190	apoptotic signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 464
KE 2195	Increase, CNS Neural cell death	GO:0008219	cell death	describes	medium	marvinm2	2026-07-28	AOP 471, AOP 569
KE 2201	Agonism, Retinoic acid receptor	GO:0048384	retinoic acid receptor signaling pathway	involves	high	marvinm2	2026-07-28	AOP 520, AOP 523, AOP 532
KE 2202	Altered expression of cell cycle genes	GO:0000278	mitotic cell cycle	describes	high	marvinm2	2026-07-28	AOP 520, AOP 523, AOP 581
KE 2203	Decreased proliferation of cortical neural progenitor cells	GO:0061351	neural precursor cell proliferation	describes	high	marvinm2	2026-07-28	AOP 520, AOP 523, AOP 581
KE 2204	Altered brain morphology	GO:0048854	brain morphogenesis	describes	medium	marvinm2	2026-07-28	AOP 520
KE 2208	Aberrant, synaptic formation and plasticity	GO:0007416	synapse assembly	involves	medium	marvinm2	2026-07-28	AOP 522, AOP 535
KE 2208	Aberrant, synaptic formation and plasticity	GO:0048167	regulation of synaptic plasticity	involves	medium	marvinm2	2026-07-28	AOP 522, AOP 535
KE 2210	Reduced cortical thickness	GO:0021987	cerebral cortex development	describes	medium	marvinm2	2026-07-28	AOP 523
KE 2216	Binding of antagonist to thyroid hormone receptor	GO:0002154	thyroid hormone receptor signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 525
KE 2217	Binding of antagonist to glucocorticoid hormone receptor	GO:0042921	nuclear receptor-mediated glucocorticoid signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 525
KE 2218	Binding of (ant)agonist to liver X receptor	GO:0141193	nuclear receptor-mediated signaling pathway	involves	low	marvinm2	2026-07-28	AOP 525
KE 2219	Binding of (ant)agonist to peroxisome proliferator–activated receptor alpha	GO:0035357	peroxisome proliferator activated receptor signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 525
KE 2220	Antagonism, Glucocorticoid hormone receptor	GO:0042921	nuclear receptor-mediated glucocorticoid signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 525
KE 2221	Altered Liver X receptor activity	GO:0141193	nuclear receptor-mediated signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 525
KE 2222	Altered peroxisome proliferator–activated receptor alpha activity	GO:0035357	peroxisome proliferator activated receptor signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 525
KE 2223	Reduced number of oligodendrocytes	GO:0048709	oligodendrocyte differentiation	involves	medium	marvinm2	2026-07-28	AOP 525
KE 2223	Reduced number of oligodendrocytes	GO:0070444	oligodendrocyte progenitor proliferation	involves	medium	marvinm2	2026-07-28	AOP 525
KE 2232	Antagonism, Retinoic acid receptors	GO:0048384	retinoic acid receptor signaling pathway	involves	high	marvinm2	2026-07-28	AOP 533
KE 2233	Decreased, ERαβ heterodimers	GO:0030520	estrogen receptor signaling pathway	involves	high	marvinm2	2026-07-28	AOP 535
KE 2262	Neuropathy target esterase, inhibited	GO:0006644	phospholipid metabolic process	related	medium	marvinm2	2026-07-28	AOP 543, AOP 544
KE 2263	Lysolecithin, increased	GO:0006644	phospholipid metabolic process	related	medium	marvinm2	2026-07-28	AOP 543, AOP 544
KE 2264	Lysolecithin cell membrane integration, increased	GO:0061024	membrane organization	related	low	marvinm2	2026-07-28	AOP 543
KE 1214	Altered gene expression specific to CAR activation, Hepatocytes	GO:0141193	nuclear receptor-mediated signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 107
KE 25	Agonism, Androgen receptor	GO:0030521	androgen receptor signaling pathway	involves	high	marvinm2	2026-07-28	AOP 117, AOP 23, AOP 376, AOP 495, AOP 496, AOP 547
KE 18	Activation, AhR	GO:0030522	intracellular receptor signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 131, AOP 150, AOP 151, AOP 21, AOP 310, AOP 414, AOP 415, AOP 416, AOP 417, AOP 418, AOP 419, AOP 420, AOP 439, AOP 455, AOP 456, AOP 458, AOP 459, AOP 494, AOP 563, AOP 57, AOP 577, AOP 578
KE 280	Thyroxine (T4) in neuronal tissue, Decreased	GO:0042403	thyroid hormone metabolic process	involves	medium	marvinm2	2026-07-28	AOP 134, AOP 152, AOP 42, AOP 458, AOP 459, AOP 54, AOP 65, AOP 8
KE 280	Thyroxine (T4) in neuronal tissue, Decreased	GO:0070327	thyroid hormone transport	involves	medium	marvinm2	2026-07-28	AOP 134, AOP 152, AOP 42, AOP 458, AOP 459, AOP 54, AOP 65, AOP 8
KE 402	Cognitive function, decreased	GO:0050890	cognition	describes	high	marvinm2	2026-07-28	AOP 134, AOP 152, AOP 300, AOP 405, AOP 42, AOP 442, AOP 458, AOP 459, AOP 485, AOP 486, AOP 487, AOP 488, AOP 489, AOP 581, AOP 65
KE 122	Activation, Glucocorticoid Receptor	GO:0042921	nuclear receptor-mediated glucocorticoid signaling pathway	involves	high	marvinm2	2026-07-28	AOP 14, AOP 214, AOP 318, AOP 334, AOP 581, AOP 624, AOP 625, AOP 626, AOP 627, AOP 628, AOP 629
KE 202	Inhibition, Nuclear factor kappa B (NF-kB)	GO:0007249	canonical NF-kappaB signal transduction	involves	high	marvinm2	2026-07-28	AOP 14, AOP 277, AOP 278, AOP 447, AOP 618
KE 1493	Increased Pro-inflammatory mediators	GO:0002532	production of molecular mediator involved in inflammatory response	describes	medium	marvinm2	2026-07-28	AOP 144, AOP 17, AOP 293, AOP 294, AOP 377, AOP 38, AOP 432, AOP 470
KE 1494	Leukocyte recruitment/activation	GO:0030595	leukocyte chemotaxis	involves	medium	marvinm2	2026-07-28	AOP 144, AOP 293, AOP 294
KE 1494	Leukocyte recruitment/activation	GO:0045321	leukocyte activation	involves	medium	marvinm2	2026-07-28	AOP 144, AOP 293, AOP 294
KE 265	Activation, Stellate cells	GO:0035733	hepatic stellate cell activation	describes	high	marvinm2	2026-07-28	AOP 144, AOP 38, AOP 494, AOP 624, AOP 625, AOP 626, AOP 627, AOP 628, AOP 629
KE 1492	Tissue resident cell activation	GO:0001775	cell activation	describes	medium	marvinm2	2026-07-28	AOP 17, AOP 293, AOP 294, AOP 38, AOP 483
KE 1101	Altered, Amphibian metamorphosis	GO:0007552	metamorphosis	describes	high	marvinm2	2026-07-28	AOP 175, AOP 176, AOP 188, AOP 189, AOP 190, AOP 191, AOP 192, AOP 193, AOP 194, AOP 366, AOP 367
KE 1262	Apoptosis	GO:0006915	apoptotic process	describes	high	marvinm2	2026-07-28	AOP 205, AOP 207, AOP 212, AOP 285, AOP 322, AOP 393, AOP 419, AOP 439, AOP 441, AOP 452, AOP 460, AOP 476, AOP 491, AOP 500, AOP 502, AOP 535, AOP 540, AOP 563, AOP 595, AOP 616, AOP 638
KE 1394	Induction, persistent proliferation/sustained proliferation	GO:0008283	cell population proliferation	describes	high	marvinm2	2026-07-28	AOP 220
KE 41	Inhibition, Bile Salt Export Pump (ABCB11)	GO:0015722	canalicular bile acid transport	describes	high	marvinm2	2026-07-28	AOP 27
KE 115	Increase, FA Influx	GO:0015908	fatty acid transport	describes	high	marvinm2	2026-07-28	AOP 34, AOP 517
KE 116	Activation, FAS	GO:0006633	fatty acid biosynthetic process	describes	high	marvinm2	2026-07-28	AOP 34
KE 167	Activation, LXR	GO:0141209	oxysterol receptor signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 34, AOP 518, AOP 58
KE 228	peroxisome proliferator activated receptor promoter demethylation	GO:0141166	chromosomal 5-methylcytosine DNA demethylation pathway	related	medium	marvinm2	2026-07-28	AOP 34, AOP 510, AOP 58, AOP 72
KE 258	Activation, SCD-1	GO:0006636	unsaturated fatty acid biosynthetic process	describes	high	marvinm2	2026-07-28	AOP 34
KE 264	Activation, SREBP-1c	GO:0032933	SREBP signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 34
KE 54	Up Regulation, CD36	GO:0015908	fatty acid transport	describes	medium	marvinm2	2026-07-28	AOP 34, AOP 517, AOP 57, AOP 58, AOP 60
KE 233	Decreased, PPAR-gamma activation	GO:0035357	peroxisome proliferator activated receptor signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 36, AOP 513
KE 165	Activation, Long term AHR receptor driven direct and indirect gene expression changes	GO:0030522	intracellular receptor signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 41
KE 409	Metabolism of AFB1, Production of Reactive Electrophiles	GO:0046222	aflatoxin metabolic process	related	medium	marvinm2	2026-07-28	AOP 46
KE 493	Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts	GO:0006281	DNA repair	describes	high	marvinm2	2026-07-28	AOP 46
KE 239	Activation, Pregnane-X receptor, NR1l2	GO:0141193	nuclear receptor-mediated signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 517, AOP 545, AOP 548, AOP 8
KE 715	Activation, Constitutive androstane receptor	GO:0141193	nuclear receptor-mediated signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 107
KE 245	Activation, PXR/SXR	GO:0141193	nuclear receptor-mediated signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 11, AOP 60
KE 55	Increase, Cell injury/death	GO:0008219	cell death	describes	high	marvinm2	2026-07-28	AOP 12, AOP 13, AOP 144, AOP 17, AOP 264, AOP 265, AOP 266, AOP 268, AOP 273, AOP 278, AOP 281, AOP 325, AOP 331, AOP 333, AOP 377, AOP 38, AOP 479, AOP 48, AOP 490, AOP 494, AOP 530, AOP 596, AOP 599, AOP 624, AOP 625, AOP 626, AOP 627, AOP 628, AOP 629
KE 757	Hippocampal anatomy, Altered	GO:0021766	hippocampus development	describes	high	marvinm2	2026-07-28	AOP 134, AOP 152, AOP 300, AOP 42, AOP 442, AOP 8
KE 758	Hippocampal Physiology, Altered	GO:0007268	chemical synaptic transmission	related	medium	marvinm2	2026-07-28	AOP 134, AOP 152, AOP 300, AOP 42, AOP 442, AOP 458, AOP 459, AOP 490, AOP 8
KE 68	Accumulation, Collagen	GO:0032964	collagen biosynthetic process	involves	medium	marvinm2	2026-07-28	AOP 144, AOP 173, AOP 241, AOP 319, AOP 38, AOP 382, AOP 624, AOP 625, AOP 626, AOP 627, AOP 628, AOP 629
KE 68	Accumulation, Collagen	GO:0030574	collagen catabolic process	involves	medium	marvinm2	2026-07-28	AOP 144, AOP 173, AOP 241, AOP 319, AOP 38, AOP 382, AOP 624, AOP 625, AOP 626, AOP 627, AOP 628, AOP 629
KE 898	Disruption, Lysosome	GO:0007040	lysosome organization	describes	high	marvinm2	2026-07-28	AOP 144, AOP 257, AOP 530
KE 1539	Endocytotic lysosomal uptake	GO:0006897	endocytosis	describes	medium	marvinm2	2026-07-28	AOP 144, AOP 530
KE 961	Increased, Clearance of thyroxine from serum	GO:0042404	thyroid hormone catabolic process	describes	high	marvinm2	2026-07-28	AOP 152, AOP 162, AOP 194, AOP 366, AOP 367, AOP 458, AOP 8
KE 295	Induction, Upregulation of glucuronyltransferase activity	GO:0006805	xenobiotic metabolic process	related	medium	marvinm2	2026-07-28	AOP 162, AOP 194, AOP 458, AOP 8
KE 227	Activation, PPARα	GO:0035357	peroxisome proliferator activated receptor signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 18, AOP 323, AOP 37, AOP 401, AOP 51, AOP 61, AOP 612, AOP 613, AOP 614
KE 1157	Activation, Hepatic nuclear receptor(s)	GO:0141193	nuclear receptor-mediated signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 194
KE 1158	Increased, Hepatic thyroid hormone uptake/transport	GO:0070327	thyroid hormone transport	describes	high	marvinm2	2026-07-28	AOP 194, AOP 366, AOP 367, AOP 393
KE 1284	Up Regulation, SREBF2	GO:0032933	SREBP signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 209, AOP 401
KE 1285	Up Regulation, Unsaturated fatty acid	GO:0006636	unsaturated fatty acid biosynthetic process	describes	high	marvinm2	2026-07-28	AOP 209
KE 1286	Down Regulation, GSS and GSTs gene	GO:0006749	glutathione metabolic process	describes	medium	marvinm2	2026-07-28	AOP 209
KE 1288	Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene	GO:0006695	cholesterol biosynthetic process	describes	high	marvinm2	2026-07-28	AOP 209, AOP 594
KE 244	Alkylation, Protein	GO:0008213	protein alkylation	describes	high	marvinm2	2026-07-28	AOP 258, AOP 38
KE 87	Release, Cytokine	GO:0001816	cytokine production	describes	medium	marvinm2	2026-07-28	AOP 27, AOP 303, AOP 377, AOP 412, AOP 638
KE 288	Activation of specific nuclear receptors, Transcriptional change	GO:0141193	nuclear receptor-mediated signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 27
KE 887	Inhibition, NADH-ubiquinone oxidoreductase (complex I)	GO:0006120	mitochondrial electron transport, NADH to ubiquinone	describes	high	marvinm2	2026-07-28	AOP 273, AOP 276, AOP 3
KE 888	Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I)	GO:0006120	mitochondrial electron transport, NADH to ubiquinone	describes	high	marvinm2	2026-07-28	AOP 273, AOP 276, AOP 3
KE 111	Agonism, Estrogen receptor	GO:0030520	estrogen receptor signaling pathway	involves	high	marvinm2	2026-07-28	AOP 112, AOP 167, AOP 200, AOP 29, AOP 52, AOP 53, AOP 536, AOP 537
KE 307	Increase, Vitellogenin synthesis in liver	GO:0007296	vitellogenesis	describes	high	marvinm2	2026-07-28	AOP 29, AOP 536, AOP 537
KE 364	Impaired development of, Reproductive organs	GO:0061458	reproductive system development	describes	high	marvinm2	2026-07-28	AOP 29, AOP 537, AOP 616
KE 66	Activation, ChREBP	GO:0010255	glucose mediated signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 34, AOP 58
KE 89	Synthesis, De Novo Fatty Acid (FA)	GO:0006633	fatty acid biosynthetic process	describes	high	marvinm2	2026-07-28	AOP 34, AOP 518
KE 140	Decreased, HSD17B10 expression	GO:0006635	fatty acid beta-oxidation	related	medium	marvinm2	2026-07-28	AOP 36
KE 179	Decrease, Fatty acid beta-oxidation	GO:0006635	fatty acid beta-oxidation	describes	high	marvinm2	2026-07-28	AOP 36, AOP 497, AOP 529, AOP 599, AOP 60, AOP 600, AOP 601
KE 231	Decreased, PPAR-alpha activation	GO:0035357	peroxisome proliferator activated receptor signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 36
KE 232	Decreased, PPAR-beta activation	GO:0035357	peroxisome proliferator activated receptor signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 36
KE 462	Up Regulation, SCD-1	GO:0006636	unsaturated fatty acid biosynthetic process	describes	high	marvinm2	2026-07-28	AOP 401, AOP 57, AOP 58, AOP 60
KE 472	Down Regulation, CPT1A	GO:0006853	carnitine shuttle	describes	medium	marvinm2	2026-07-28	AOP 401, AOP 60
KE 853	Changes/Inhibition, Cellular Homeostasis and Apoptosis	GO:0019725	cellular homeostasis	involves	medium	marvinm2	2026-07-28	AOP 41
KE 853	Changes/Inhibition, Cellular Homeostasis and Apoptosis	GO:0006915	apoptotic process	involves	medium	marvinm2	2026-07-28	AOP 41
KE 854	Alterations, Cellular proliferation / hyperplasia	GO:0008283	cell population proliferation	describes	high	marvinm2	2026-07-28	AOP 41, AOP 495
KE 491	Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)	GO:0072574	hepatocyte proliferation	describes	high	marvinm2	2026-07-28	AOP 46
KE 467	Increased, LDL uptake	GO:0034383	low-density lipoprotein particle clearance	describes	medium	marvinm2	2026-07-28	AOP 462, AOP 57
KE 2199	Increased, Expression of LXR activated genes	GO:0141193	nuclear receptor-mediated signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 518
KE 216	Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)	GO:0006094	gluconeogenesis	describes	medium	marvinm2	2026-07-28	AOP 57
KE 450	Suppression, VLDL secretion	GO:0034379	very-low-density lipoprotein particle assembly	related	medium	marvinm2	2026-07-28	AOP 57
KE 451	Inhibition, Mitochondrial fatty acid beta-oxidation	GO:0006635	fatty acid beta-oxidation	describes	high	marvinm2	2026-07-28	AOP 57, AOP 58, AOP 61
KE 465	Increased, FA Influx	GO:0015908	fatty acid transport	describes	high	marvinm2	2026-07-28	AOP 57, AOP 58, AOP 60, AOP 624, AOP 625, AOP 626
KE 466	Up Regulation, LDLR (low density lipoprotein receptor)	GO:0034383	low-density lipoprotein particle clearance	describes	medium	marvinm2	2026-07-28	AOP 57
KE 454	Increased, Triglyceride formation	GO:0019432	triglyceride biosynthetic process	describes	high	marvinm2	2026-07-28	AOP 58, AOP 60
KE 456	Suppression, Constitutive androstane receptor, NR1l3	GO:0141193	nuclear receptor-mediated signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 58
KE 457	Activation, SREBF1	GO:0032933	SREBP signaling pathway	involves	high	marvinm2	2026-07-28	AOP 58, AOP 62
KE 458	Increased, De Novo FA synthesis	GO:0006633	fatty acid biosynthetic process	describes	high	marvinm2	2026-07-28	AOP 58, AOP 61
KE 463	Up Regulation, FAS	GO:0006633	fatty acid biosynthetic process	describes	high	marvinm2	2026-07-28	AOP 58
KE 468	Inhibition, PPAR alpha	GO:0035357	peroxisome proliferator activated receptor signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 58
KE 470	Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)	GO:2001295	malonyl-CoA biosynthetic process	describes	medium	marvinm2	2026-07-28	AOP 58
KE 474	Down Regulation, HMGCS2	GO:0046951	ketone body biosynthetic process	describes	high	marvinm2	2026-07-28	AOP 60
KE 478	Activation, NRF2	GO:0034599	cellular response to oxidative stress	describes	medium	marvinm2	2026-07-28	AOP 61
KE 479	Activation, NR1H4	GO:0038185	nuclear receptor-mediated bile acid signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 61
KE 480	Activation, SHP	GO:0141193	nuclear receptor-mediated signaling pathway	involves	low	marvinm2	2026-07-28	AOP 61
KE 482	Decreased, DHB4/HSD17B4	GO:0033540	fatty acid beta-oxidation using acyl-CoA oxidase	describes	medium	marvinm2	2026-07-28	AOP 61
KE 483	Activation, LXR alpha	GO:0141209	oxysterol receptor signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 61
KE 484	Activation, AKT2	GO:0043491	phosphatidylinositol 3-kinase/protein kinase B signal transduction	involves	medium	marvinm2	2026-07-28	AOP 62
KE 486	systemic inflammation leading to hepatic steatosis	GO:0006954	inflammatory response	involves	medium	marvinm2	2026-07-28	AOP 62
KE 486	systemic inflammation leading to hepatic steatosis	GO:0019915	lipid storage	involves	medium	marvinm2	2026-07-28	AOP 62
KE 57	Proliferation, Cell proliferation in the absence of cytotoxicity	GO:0008283	cell population proliferation	describes	high	marvinm2	2026-07-28	AOP 1
KE 716	Increase, cell proliferation (hepatocytes)	GO:0072574	hepatocyte proliferation	describes	high	marvinm2	2026-07-28	AOP 107, AOP 117, AOP 37
KE 724	Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme	GO:0010510	regulation of pyruvate decarboxylation to acetyl-CoA	describes	medium	marvinm2	2026-07-28	AOP 108
KE 726	Increased, Induction of pyruvate dehydrogenase (PDH)	GO:0006086	pyruvate decarboxylation to acetyl-CoA	describes	high	marvinm2	2026-07-28	AOP 108
KE 768	Increase, Cytotoxicity	GO:0008219	cell death	describes	high	marvinm2	2026-07-28	AOP 108, AOP 136, AOP 284
KE 769	Increase, Oxidative metabolism	GO:0045333	cellular respiration	describes	medium	marvinm2	2026-07-28	AOP 108
KE 739	Increase, Hypertrophy and proliferation (follicular cell)	GO:1990789	thyroid gland epithelial cell proliferation	involves	medium	marvinm2	2026-07-28	AOP 110, AOP 119, AOP 162
KE 739	Increase, Hypertrophy and proliferation (follicular cell)	GO:0016049	cell growth	involves	medium	marvinm2	2026-07-28	AOP 110, AOP 119, AOP 162
KE 786	Increase, Cytotoxicity (hepatocytes)	GO:0008219	cell death	describes	high	marvinm2	2026-07-28	AOP 118
KE 787	Increase, Regenerative cell proliferation (hepatocytes)	GO:0072574	hepatocyte proliferation	describes	high	marvinm2	2026-07-28	AOP 118
KE 828	Inhibition, Phospholipase A	GO:0009395	phospholipid catabolic process	describes	medium	marvinm2	2026-07-28	AOP 130
KE 860	Decreased, Mitochondrial Fatty Acid Beta Oxidation	GO:0006635	fatty acid beta-oxidation	describes	high	marvinm2	2026-07-28	AOP 318
KE 8	Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity	GO:0006635	fatty acid beta-oxidation	describes	medium	marvinm2	2026-07-28	AOP 36
KE 80	Up Regulation, CYP1A1	GO:0006805	xenobiotic metabolic process	describes	high	marvinm2	2026-07-28	AOP 57, AOP 646
KE 878	Inhibition, SREBP1c	GO:0032933	SREBP signaling pathway	involves	high	marvinm2	2026-07-28	AOP 61
KE 879	Activation, MTTP	GO:0034379	very-low-density lipoprotein particle assembly	describes	high	marvinm2	2026-07-28	AOP 61
KE 880	Increased, ApoB100	GO:0034379	very-low-density lipoprotein particle assembly	related	medium	marvinm2	2026-07-28	AOP 61
KE 881	Increased, Triglyceride	GO:0019432	triglyceride biosynthetic process	involves	medium	marvinm2	2026-07-28	AOP 61
KE 881	Increased, Triglyceride	GO:0019433	triglyceride catabolic process	involves	medium	marvinm2	2026-07-28	AOP 61
KE 2224	Dysregulation of transcriptional expression within PPAR signaling network	GO:0035357	peroxisome proliferator activated receptor signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 529
KE 2225	Disrupted Lipid Storage	GO:0019915	lipid storage	describes	high	marvinm2	2026-07-28	AOP 529
KE 2226	Stressor binding PPAR isoforms	GO:0035357	peroxisome proliferator activated receptor signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 529
KE 2227	Disrupted PPAR isoform nuclear signaling	GO:0035357	peroxisome proliferator activated receptor signaling pathway	describes	high	marvinm2	2026-07-28	AOP 529
KE 1104	Decreased, Prostaglandin F2alpha concentration, plasma	GO:0006693	prostaglandin metabolic process	describes	high	marvinm2	2026-07-28	AOP 177
KE 1106	Occurrence, cardiac arrhythmia	GO:0061337	cardiac conduction	describes	medium	marvinm2	2026-07-28	AOP 138, AOP 177, AOP 186, AOP 551, AOP 554, AOP 559, AOP 560, AOP 562
KE 1171	Increase, Clonal Expansion of Altered Hepatic Foci	GO:0072574	hepatocyte proliferation	describes	medium	marvinm2	2026-07-28	AOP 37
KE 1177	Decreased, Ionotropic GABA receptor chloride channel conductance	GO:0007214	gamma-aminobutyric acid signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 471
KE 1270	Inactivation of PPARγ	GO:0035357	peroxisome proliferator activated receptor signaling pathway	involves	medium	marvinm2	2026-07-28	AOP 206, AOP 347
KE 1271	Activation of TGF-β signaling	GO:0007179	transforming growth factor beta receptor signaling pathway	describes	high	marvinm2	2026-07-28	AOP 206, AOP 624, AOP 625, AOP 626, AOP 627, AOP 628, AOP 629
KE 1275	Collagen Deposition	GO:0032964	collagen biosynthetic process	describes	medium	marvinm2	2026-07-28	AOP 206
KE 1276	Lung fibrosis	GO:0030198	extracellular matrix organization	related	medium	marvinm2	2026-07-28	AOP 206, AOP 319, AOP 382, AOP 414, AOP 415
KE 1289	Perturbation of cholesterol	GO:0042632	cholesterol homeostasis	describes	high	marvinm2	2026-07-28	AOP 209
KE 1305	Increase, cytosolic fatty acid	GO:0006631	fatty acid metabolic process	involves	medium	marvinm2	2026-07-28	AOP 213
KE 1305	Increase, cytosolic fatty acid	GO:0015908	fatty acid transport	involves	medium	marvinm2	2026-07-28	AOP 213
KE 1349	Activated, presynaptic neuron 1	GO:0098928	presynaptic signal transduction	involves	medium	marvinm2	2026-07-28	AOP 215, AOP 230, AOP 471
KE 1362	Increased, hippocampal hyperdepolarization	GO:0051899	membrane depolarization	describes	high	marvinm2	2026-07-28	AOP 215, AOP 230, AOP 231
KE 1365	Increase, Apoptosis	GO:0006915	apoptotic process	describes	high	marvinm2	2026-07-28	AOP 330, AOP 444, AOP 447, AOP 509, AOP 622
KE 1352	Activated, voltage-gated sodium channel	GO:0035725	sodium ion transmembrane transport	describes	high	marvinm2	2026-07-28	AOP 215, AOP 230
KE 1355	Activated, membrane depolarization	GO:0051899	membrane depolarization	describes	high	marvinm2	2026-07-28	AOP 215, AOP 230, AOP 231
KE 1321	Increased, intracellular sodium (Na+)	GO:0006883	intracellular sodium ion homeostasis	describes	high	marvinm2	2026-07-28	AOP 214, AOP 215, AOP 230, AOP 556
KE 1287	Glutathione synthesis	GO:0006750	glutathione biosynthetic process	describes	high	marvinm2	2026-07-24	AOP 209
KE 1490	Inhibition, Fatty Acid Beta Oxidation	GO:0006635	fatty acid beta-oxidation	describes	high	marvinm2	2026-07-23	AOP 213
KE 1825	Increase, Cell death	GO:0008219	cell death	describes	high	marvinm2	2026-07-22	AOP 287, AOP 291, AOP 368, AOP 377, AOP 410, AOP 418, AOP 464, AOP 468, AOP 472, AOP 482, AOP 573, AOP 574
KE 1194	Increase, DNA damage	GO:0006974	DNA damage response	describes	high	marvinm2	2026-07-22	AOP 200, AOP 293, AOP 294, AOP 388, AOP 396, AOP 423, AOP 432, AOP 435, AOP 441, AOP 444, AOP 472, AOP 476, AOP 591, AOP 645
KE 149	Increase, Inflammation	GO:0006954	inflammatory response	describes	high	marvinm2	2026-07-22	AOP 115, AOP 206, AOP 27, AOP 280, AOP 439, AOP 472, AOP 505, AOP 544, AOP 577
KE 1115	Increase, Reactive oxygen species	GO:0072593	reactive oxygen species metabolic process	describes	high	marvinm2	2026-07-18	AOP 186, AOP 207, AOP 213, AOP 26, AOP 27, AOP 273, AOP 282, AOP 298, AOP 299, AOP 303, AOP 311, AOP 319, AOP 324, AOP 325, AOP 326, AOP 327, AOP 328, AOP 329, AOP 330, AOP 331, AOP 332, AOP 333, AOP 382, AOP 383, AOP 384, AOP 386, AOP 387, AOP 396, AOP 409, AOP 413, AOP 416, AOP 418, AOP 423, AOP 451, AOP 462, AOP 472, AOP 476, AOP 481, AOP 488, AOP 492, AOP 497, AOP 500, AOP 505, AOP 511, AOP 513, AOP 521, AOP 534, AOP 540, AOP 569, AOP 595, AOP 596, AOP 598, AOP 599, AOP 600, AOP 601, AOP 602, AOP 603, AOP 608, AOP 613, AOP 622, AOP 636, AOP 638
KE 1392	Oxidative Stress	GO:0006979	response to oxidative stress	describes	high	marvinm2	2026-07-18	AOP 138, AOP 17, AOP 171, AOP 177, AOP 186, AOP 200, AOP 220, AOP 26, AOP 260, AOP 284, AOP 31, AOP 324, AOP 325, AOP 326, AOP 331, AOP 332, AOP 333, AOP 377, AOP 396, AOP 411, AOP 424, AOP 425, AOP 429, AOP 437, AOP 444, AOP 447, AOP 450, AOP 452, AOP 457, AOP 459, AOP 462, AOP 464, AOP 470, AOP 471, AOP 472, AOP 476, AOP 478, AOP 479, AOP 481, AOP 482, AOP 483, AOP 488, AOP 497, AOP 501, AOP 505, AOP 507, AOP 509, AOP 510, AOP 511, AOP 521, AOP 534, AOP 535, AOP 538, AOP 540, AOP 595, AOP 596, AOP 598, AOP 599, AOP 600, AOP 601, AOP 602, AOP 603, AOP 608, AOP 616, AOP 622, AOP 625, AOP 628, AOP 642, AOP 645, AOP 646
KE 1097	Occurrence, renal proximal tubular necrosis	GO:0097300	programmed necrotic cell death	describes	medium	marvinm2	2026-07-18	AOP 138, AOP 177, AOP 186, AOP 447, AOP 472
KE 177	Mitochondrial dysfunction	GO:0007005	mitochondrion organization	involves	medium	marvinm2	2026-07-18	AOP 130, AOP 144, AOP 178, AOP 200, AOP 205, AOP 207, AOP 256, AOP 258, AOP 273, AOP 3, AOP 335, AOP 34, AOP 362, AOP 377, AOP 423, AOP 437, AOP 447, AOP 464, AOP 472, AOP 476, AOP 479, AOP 48, AOP 480, AOP 481, AOP 497, AOP 500, AOP 509, AOP 511, AOP 530, AOP 587, AOP 588, AOP 589, AOP 595, AOP 622, AOP 624, AOP 627, AOP 636, AOP 77, AOP 78, AOP 79, AOP 80, AOP 87
KE 57	Proliferation, Cell proliferation in the absence of cytotoxicity	GO:0051301	cell division	describes	medium	SidraAdil	2026-05-10	AOP 1
KE 142	Hyperplasia, Hyperplasia	GO:0014738	regulation of muscle hyperplasia	describes	high	SidraAdil	2026-05-10	AOP 1
KE 334	Promotion, Hepatocelluar carcinoma	GO:2000345	regulation of hepatocyte proliferation	involves	medium	SidraAdil	2026-05-10	AOP 1
KE 214	Bile accumulation, Pathological condition	GO:0015721	bile acid and bile salt transport	describes	medium	SidraAdil	2026-05-10	AOP 27
KE 55	Increase, Cell injury/death	GO:0006915	apoptotic process	involves	high	marvinm2	2026-02-07	AOP 12, AOP 13, AOP 144, AOP 17, AOP 264, AOP 265, AOP 266, AOP 268, AOP 273, AOP 278, AOP 281, AOP 325, AOP 331, AOP 333, AOP 377, AOP 38, AOP 479, AOP 48, AOP 490, AOP 494, AOP 530, AOP 596, AOP 599, AOP 624, AOP 625, AOP 626, AOP 627, AOP 628, AOP 629

Sign in